Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study - Articles - Oncology · Hematology

Skin Cancer

Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system

Eur J Cancer

Samaran Q, Bettuzzi T, Sbidian E

doi: 10.1016/j.ejca.2026.116585

Skin Cancer

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study

Eur J Cancer

Pedersen S, Colmorn LB, Ellebaek E, Kristensen SG, Ruhlmann C, Borch TH, Donia M, Fedder J, Macklon KT, Svane IM

doi: 10.1016/j.ejca.2026.116584

Skin Cancer

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Int J Cancer

Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D

doi: 10.1002/ijc.70440

Lung, Respiratory and Thoracic Cancer

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Lancet Oncol

Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi JV, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino MC, Peters S, Awad MM, Ardizzoni A, Ricciuti B

doi: 10.1016/S1470-2045(25)00429-2

Non-Malignant Blood Disorders

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Br J Haematol

Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H

doi: 10.1111/bjh.70531

Gastrointestinal Cancer

Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study

Eur J Cancer

Ghedri A, van der Baan FH, Otten JMMB, Elferink MAG, Terheggen F, Hendriks MP, May AM, Koopman M, Punt CJA, Kwakman JJM, PLCRC study group

doi: 10.1016/j.ejca.2026.116588

Lung, Respiratory and Thoracic Cancer

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50

J Thorac Oncol

Socinski MA, Reck M, Paz-Ares L, Nishio M, Spira AI, Yu X, Melkadze T, Zeng A, Martinez-Bueno A, Li X, Arulananda S, Zuo Y, Chica-Duque S, Dai W, Zhou J, Tan W, Lu S

doi: 10.1016/j.jtho.2026.104089

Myeloproliferative Neoplasms (MPNs)

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

Leuk Lymphoma

Kuykendall AT, Palandri F, Fillbrunn M, Liu T, Zhang S, Zhang A, Simpson R, Sajeev G, Signorovitch J, Patnaik D, Gerds AT

doi: 10.1080/10428194.2026.2628361

Multiple Myeloma (MM)

Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database

Leuk Lymphoma

Nieto MJ, Shih YH, Fang J, Qiu Y, Gentili C, Hernandez Rivera G

doi: 10.1080/10428194.2026.2702128

Related content

Comparative effectiveness of first-line anti-PD-1 versus cetuximab in advanced cutaneous squamous cell carcinoma: A nationwide population-based study using the French national health data system

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study

Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database